Intermittent androgen deprivation after psa-complete response as a strategy to reduce induction of hormone-resistant prostate cancer

Urology

Volumn 49, Issue 1, 1997, Pages 79-82

  Oliver, R T D ^a   Williams, Grant ^a   Paris, A M I ^a   Blandy, J P ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER THERAPY; CLINICAL ARTICLE; DISEASE ASSOCIATION; HORMONE DEFICIENCY; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RELAPSE; RETROSPECTIVE STUDY; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 0031015463     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00373-1     Document Type: Article

References (16)

1. Crawford ED, Eisenberger MA, McLead DG, Spaulding JT, Benson R, Doss A, Blumenstein BA, Davis MA, and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989.
2. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, and Sullivan LD: Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 71: 2782-2790, 1993.
3. Goldenberg SL, Bruchovsky N, Cleave ME, Sullivan LD, and Akakura K: Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45: 839-845, 1995.
4. Oliver RTD: Risking less treatment in cancer patients: lessons from germ-cell tumours. Lancet 2: 430-431, 1988.
5. Pilepich MV, Krall J, Al-Sarraf M, John MJ, Doggett RLS, Sause WT, Lawton CA, Abrams RA, Rotman M, and Rubin P: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation-Therapy Oncology Group. Urology 45: 616-623, 1995.
6. Rana A, Habib FK, Halliday P, Ross M, Wild R, Elton RA, and Chishold GD: A case for synchronous reduction of testicular androgen, andrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate. Eur J Cancer 31: 871-875, 1995.
7. Oliver R, and Gallagher C: Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer. Cancer Surv 23: 191-207, 1995.
8. Oliver RTD, Joseph JV, and Gallagher CJ: Castration-induced lymphocytosis in prostate cancer: possible evidence for gonad/thymus endocrine interaction in man. Urol Int 54: 226-229, 1995.
9. Grossman CJ: Interactions between the gonadal-steroids and the immune system. Science 227: 257-261, 1985.
10. Sperandio P, Tomio P, Oliver RTD, Fiorentino MV, and Pagano F: Gonadal atrophy as a cause of thymic hyperplasia after chemotherapy. Br J Cancer (in press).
11. Kosaka A, Hattori Y, Imaizumi A, and Yamashita A: Synergistic effect of lentinan and surgical endocrine therapy of the growth of DMBA-induced mammary tumours of rats and of recurrent human breast cancer. Excerpta Medica International Conference 690: 138-199, 1985.
12. Oliver RTD: Topical BCG for recurrent superficial bladder cancer. Lancet 337: 821-822, 1991.
13. Richardson A: The effect of condom use in squamous cell cervical intraepithelial neoplasia. Am J Obstet Gynecol 140: 909-913, 1981.
14. Reid B, French P, and Singer A: Sperm basic proteins in cervical carcinogenesis: correlation with socioeconomic class. Lancet 2: 60-64, 1978.
15. Schmid H, McNeal JE, and Stamey TA. Observations on the doubling time of prostate cancer. Cancer 71: 2031-2040, 1993.
16. Blandy JP: Surgery from a UK perspective. Cancer Surv 23: 311-314, 1995.